Second in our list is Dynavax Technologies Corporation (NASDAQ:DVAX), whose shares are up by around 16.5% today after the company announced better results from its hepatitis B vaccine, HEPLISAV-B, as compared with Engerix-B, a currently marketed vaccine. The results of the late-stage study, showed that the vaccine is more safe and more efficient than the existing product. Furthermore, Dynavax plans to open a strategic partnership for commercialization of the vaccine. The drugmaker will submit the regulatory application to the FDA by March. Dynavax Technologies Corporation (NASDAQ:DVAX) also gained popularity in the third quarter and, out of the 730 funds that we track, 32 funds held shares on September 30, amassing 36.9% of the float. Samuel Isaly‘s OrbiMed Advisors has the most valuable position in Dynavax Technologies, worth $60.67 million at the end of September.